PD-L1 testing using the Ventana 2P263 assay, with expression on ≥25% of either ICs or TCs classified as PD-L1 high. An initial report included 61 patients treated in the expansion cohort, 42 of which were response evaluable[26]. Among these patients, 28 were PD-L1 positive by TC orIC...
The pharmacokinetics of durvalumab were not affected to a clinically relevant extent by age (19–96 years), body weight (31–149 kg), sex, albumin levels, lactate dehydrogenase levels, creatinine levels, soluble PD-L1, tumour type, race, mild or moderate kidney impairment, mild hepatic impairme...
despite relatively similar patient demographic and clinical characteristics; however, it should be acknowledged that data pertaining to ECOG performance status, PD-L1 tumor cell expression, and molecular testing (ie, the presence of an EGFR variant), all of which can impact immunotherapy decisions in...
multi-center trial of IMFINZI®(durvalumab) as treatment in ”all-comer” patients (i.e., regardless of PD-L1 status) with unresectable Stage III NSCLC whose disease has not progressed following platinum-based chemotherapy concurrent with ...
IMFINZI(durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumor’s immune-evading tactics and releasing the inhibition...
Hierarchical Multiple Testing Procedure eFigure 3. Subgroup Analysis of Overall Survival for Durvalumab Monotherapy Versus Chemotherapy Among Patients With PD-L1 TC ≥25% eFigure 4. TMB Dataset and Blood TMB Correlation With Tissue TMB eFigure 5. Overall Survival in the ITT, Blood and Tissue TMB...
The impact of single-agent antibodies against programmed death-ligand 1 (PD-L1) as maintenance therapy is unknown in patients with metastatic breast cancer. The SAFIR02-BREAST IMMUNO substudy included patients with human epidermal growth factor receptor type 2 (Her2)-negative metastatic breast cancer...
Molecular testing should be mandatory for patients with stage III NSCLC. • Clinical trials should investigate the best adjuvant treatment in this setting. Abstract Adjuvantdurvalumabis the standard of care for patients with stage III unresectable non-small cell lung cancer (NSCLC), without progressio...
In animal models, inhibition of PD-L1/PD-1 signaling increased the severity of some infections and enhanced inflammatory responses. Mycobacterium tuberculosis-infected PD-1 knockout mice exhibit markedly decreased survival compared with wild-type controls, which correlated with increased bacterial proliferat...
Pretreatment tumor tissue samples were available for 261 patients for central PD-L1 TC testing (87% of those randomized) and bTMB data for 236 patients (78.4% of those randomized). The remaining patients had insufficient tissue samples for submission or PD-L1 scoring or insufficient plasma or ce...